Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Indivior Pharmaceuticals, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
INDV · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$28.15+2.6%Nov 2 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Indivior sells monthly buprenorphine injections and other opioid-addiction medicines to wholesalers, pharmacies, hospitals and health care providers.
Company outlook: revenue of $1.3B to $1.4B for Fiscal year 2026 — up 7.3% on a year earlier, slower than the 13.4% just reported